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Abstract: Etoposide, doxorubicin and cisplatin plus oral mitotane (EDP-M) comprise the reference
regimen in the management of patients with adrenocortical carcinoma (ACC). In this paper,
we described the outcome of 58 patients with advanced/metastatic ACC consecutively treated
with EDP-M in a reference center for this rare disease in Italy. In this series, EDP-M obtained
a partial response in 50% of patients; median progression free survival (PFS) and overall survival
were 10.1 months (95% Confidence Interval [CI 95%] 8.1–12.8) and 18.7 months (95% CI: 14.6–22.8),
respectively. EDP-M was not interrupted in five patients showing disease progression after two
cycles without the appearance of new lesions and mitotane levels below the therapeutic range. In two
of them, the disease remained stable at further imaging evaluations and the other three obtained
a partial response. Twenty-six responding patients underwent surgery of residual disease and 13 of
them became disease free. Surgery identified a pathological complete response (pCR) in four patients
(7%) and Ki67 expression in post-chemotherapy tumor specimens, inferior to 15% (median value),
was associated with better PFS and survival. In the present study, the EDP-M regimen is confirmed
to have a limited efficacy. Early disease progression does not mean treatment inefficacy. Surgery of
residual disease in partially responding patients allows for the detection of pCR in few of them and
this condition is predictive of long-term survival. Ki67 expression of post-chemotherapy residual
disease could be an additional prognostic factor that deserves to be studied further.
Keywords: adrenocortical tumor; treatment; EDP; mitotane
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1. Introduction
Adrenocortical carcinoma (ACC) is a rare tumor with an estimated incidence in Western countries
of 0.7–2 new cases per million population per year [1].
Surgery is the mainstay of therapy and represents the only treatment modality able to offer
a chance of a cure. Unfortunately, in half of patients the disease is diagnosed at an advanced stage
and most patients radically resected are destined to relapse within the first 2 years [1,2]. Advanced
ACC patients, not eligible for surgery, are referred to systemic antineoplastic therapies. For decades,
mitotane has been the reference drug for ACC. This compound is efficacious when serum levels reach
the so-called therapeutic range (14–20 mg/L) [3], which is not usually attained before 2–3 months
of therapy. The delayed efficacy of mitotane provides the main rationale for its association with
chemotherapy. Chemotherapy in fact exerts a cytotoxic effect in the first months of treatment when
mitotane levels are not in the therapeutic range [1]. Mitotane was also found to potentiate the
cytotoxicity of certain chemotherapeutic drugs by interfering with the multidrug resistant gene 1
product P glycoprotein (Pgp), which is also expressed by ACCs [4,5]. The combination of etoposide,
doxorubicin and cisplatin (EDP) is the standard chemotherapy regimen to be associated with mitotane
(EDP-M) [2]. An EDP-M scheme was first introduced in 1992, when it was found to be active in the
management of two young ACC patients, both obtaining a partial response lasting 7 and 21 months,
respectively [6]. The feasibility of this regimen was subsequently assessed on 7 consecutive patients [7],
then a formal prospective phase II trial was designed and conducted in Italy. The preliminary data of
this prospective trial were published in 1998 [8] and the final results were published in 2005 [9]. In the
Italian trial, the EDP-M regimen led to an overall response rate of 48.6% (95% CI: 37.1–60.3), 6.9% of
patients attained a clinical complete response. The median progression free survival (PFS) and overall
survival (OS) of the entire cohort were 9.1 and 28.5 months, respectively [9].
These data prompted the design and the conduction of a multicenter, multinational prospective
phase III trial (the FIRM-ACT trial), in which the efficacy of the EDP-M regimen was compared to
that of streptozotocyn plus mitotane (SZ-M) [10]. In this trial, patients receiving EDP-M obtained
a significantly better response rate and PFS than those submitted to SZ-M. The OS also favored EDP-M
(just failing to attain statistical significance), despite the crossover design of the study. The median time
to progression (TTP) and OS of EDP-M treated patients were 5 months and 14.8 months, respectively,
and 21% of patients were alive and free from progression after 2 years. Although the results of
this multicenter randomized clinical trial revealed that EDP-M regimen has a limited efficacy in the
management of advanced ACC patients, it is the only recommend treatment by current guidelines [2].
Modern therapies, such as molecular target therapy [11] and immunotherapy [12,13], have failed to
demonstrate a clear efficacy in the management of ACC up to now. While we are waiting for new
treatment strategies, we have to use the EDP-M scheme at its highest potential. In this paper, we present
the outcome of a consecutive series of patients with advanced/metastatic ACC treated with EDP-M at
a tertiary referral oncology center in Italy. The primary aim was to evaluate outcome measures such as
disease response, PFS and OS, secondary aims were to evaluate the prognostic role of cytoreductive
surgery, performed in patients attaining disease response and stabilization, and the prognostic role of
Ki67 expression in residual disease specimens after surgery. According to this experience, we also
provided some recommendations on how to best use the EDP-M regimen.
2. Results
2.1. Patients Characteristics
From January 2012 to January 2020, 58 consecutive patients with stage III or IV ACC underwent
the EDP-M chemotherapy regimen at the Medical Oncology Unit at Azienda Socio Sanitaria Territoriale
(ASST) Spedali Civili in Brescia. Their characteristics are summarized in Table 1.
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Table 1. Patients’ characteristics.
Patients’ Characteristics Number Percentage
No of patients 58 (100%)
Median Age (range) 47 [range 19–72]
Male/Female ratio 18/40 (69%)
mENSAT stage at Diagnosis
III 6 (10%)
IVa 25 (43%)
IVb 15 (26%)
IVc 12 (21%)
Hormone Hypersecretion at Diagnosis
Cortisol alone 9 (16%)
Cortisol plus other hormones 18 (31%)
Androgens alone 2 (3.4%)
Estrogens alone 1 (1.7%)
Aldosterone alone 1 (1.7%)
Previous treatments: Surgery 35 (60.3%)
Adjuvant Mitotane 26 (44.8%)
Mitotane for advanced disease 13 (22.4%)
GRAS score* (40 available patients)
Favorable 4 (7%)
Unfavorable 11 (19%)
Pejorative 25 (43%)
* Grade, R status, Age and Symptoms (GRAS).
The median age at diagnosis of ACC was 47 years (range 19–72); the male/female ratio was
18/40. At baseline conditions, six patients (10%) had unresectable locally advanced disease (stage III),
the remaining 52 patients (90%) had metastatic disease (stage IV). According to modified European
Network for the Study of Adrenal Tumors (ENSAT) classification (mENSAT), 25 patients (43%)
presented at least two organs involved (stage IVa), 15 (26%) had three of their organs involved in the
disease (stage IVb), and the remaining 12 patients (21%) had more than three tumor-involved organs
(stage IVc). We also defined the Grade, R status, Age and Symptoms (GRAS) score [14] in 40 evaluable
patients. Four of them (7%) were scored as GRAS grade 1, 11 patients (19%) were classified as grade 2
and 25 (43%) as grade 3. Thirty-one out of the 58 evaluable patients (53%) had hormone hypersecretion,
which consisted in cortisol alone in nine patients (16%), or cortisol plus other hormones (androgens,
estrogens and aldosterone) in 18 patients (31%). Two patients (3.4%) presented androgen hypersecretion
alone, one patient (1.7%) presented estrogen and one (1.7%) presented aldosterone hypersecretion.
The median follow-up period for patients was 34 months (range: 12–145). At the last follow-up
examination, on February 15th 2020, 38 patients (66%) were dead.
2.2. Treatment
A total of 280 EDP cycles were administered (median 5.5, range 1–8). Twenty-nine patients
(50%) completed the treatment plan (at least six cycles); among them, 22 (38%) received six cycles,
three patients (5%) received seven cycles and four patients received (7%) eight cycles.
EDP-M therapy was associated with drugs able to induce a fast decrease in serum cortisol levels in
11 patients with Cushing syndrome. In particular, five of them received metyrapone and six received
abiraterone, the last ones within a prospective clinical trial (ABACUS trial NCT 03145285).
EDP-treatment was interrupted before the sixth cycle in 29 patients (50%) for the following reasons:
progressive disease in 14 patients (24%), eligibility for surgical resection of the residual disease in
10 patients (17%), toxic death due to hemorrhagic shock, as a consequence of massive gastric bleeding,
in one patient (2%).
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Moreover, four patients discontinued the chemotherapy due to severe asthenia and performance
status (PS) deterioration, despite disease stabilization, at the fifth, fifth, fourth and third
cycles, respectively.
The most frequent toxicities were asthenia (grade 1 or 2) in 31 patients (53%), followed by
gastrointestinal side effects, such as nausea and vomiting in 23 patients (40%), diarrhea in three patients
(5.2%) and constipation in four (7%). G1/G2 hematological toxicity at treatment recycle was found
in 18 patients (31%), including a reduction in the absolute number of white blood cells or platelets.
Both grade 3 neutropenia and grade 4 thrombocytopenia at recycle were observed in two patients
(3.4%). One death was potentially related to EDP-M scheme toxicity (hemorrhagic shock caused by
massive gastric bleeding).
2.3. Outcome Measures
Median PFS in this series was 10.1 months (CI 95%: 8.1–12.8), (Figure 1).
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According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria [15], no clinical
complete responses were recorded. Twenty-nine patients achieved a clinical partial response (50%),
15 (26%) a stable disease, while disease progression was observed in 14 patients (24%). Early disease
progression (after one to two cycles) was observed in five patients. In particular, three of them had
a deterioration of PS whereas the other two had an increase in the number of metastasis. In five
additional patients, however, whose disease progression at the first radiological evaluation after two
cycles was characterized by an increase in the size of metastatic lesions already present at baseline
(without the appearance of new lesions), the treatment was not discontinued. Mitotane serum level
was below the therapeutic range in all of them. After two additional cycles, the disease remained stable
in two patients, while a partial response was observed in the remaining three. Mitotane attained the
therapeutic range after three months from treatment start in two patients and after four months in the
remaining three. Interestingly, one of these patients with mediastinal disease was addressed to surgery
and a pathological complete response was observed at the histology of the residual disease (Figure 3).
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Figure 3. Thorax CT scan series of a patient attaining a pathological complete response after six cycles
of etoposide, doxorubicin and cisplatin plus oral mitotane (EDP-M).
Twenty-six patients with disease response or stabilization underwent a surgical resection of the
residual disease. Twenty-five were submitted to abdominal surgery: laparotomy was adopted in 24 of
them and laparoscopy in the remaining one. One patient underwent complete resection of a mediastinal
metastasis. Abdominal surgery was followed by hyperthermic intraperitoneal chemotherapy treatment
(HIPEC) in 14 patients. A disease-free status was attained in 13 patients that were operated on
(50%)—12 after just one surgery and one after abdominal surgery followed by surgical removal of
a mediastinal lesion performed 3 months later. On the contrary, a residual disease ≤10% persisted
in 13 patients (50%) due to incomplete resection (R1 disease) in five of them or to the concomitant
presence of small lung metastases in the remaining eight.
A post-surgery histological evaluation of the residual disease revealed a pathologically complete
response (pCR) in four patients (7%). All these patients continued mitotane therapy after surgery and
none of them had disease recurrence at the last follow-up examination after 30+, 27+, 10+, and 8+
months, respectively.
2.4. Prognostic Role of Debulking Surgery after EDP-M and Ki67 Expression in the Residual Disease
Patients who had surgery after a disease response to EDP-M obtained a better PFS than their
counterparts: median 13.1 months (CI 95%: 10.3–15.9) versus 7.4 months (CI 95%: 5.5–9.3, p = 0.053),
(Figure 4).
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3. Discussion
In this series of advanced/metastatic ACC patients, uniformly treated in a reference oncology
center for this rare disease in Italy, the EDP-M regimen was confirmed to be active. Both the overall
response rate (ORR) according to RECIST criteria (50%) and the PFS (median 10 months) observed in
this study were higher than the ones reported with EDP-M in the FIRM-ACT trial and were similar
to those observed in the Italian phase 2 trial [9,10]. Moreover, the OS of the present ACC series was
slightly longer than that of the FIRM-ACT trial, but inferior to the one observed in the published
phase II study. These differences are not surprising, the efficacy of systemic antineoplastic therapies in
oncology literature is often heterogeneous depending on patient selection and it appears higher in
monocentric series and in phase II trials than in large multicentric clinical trials. In addition, in this
series, the EDP-M was associated with side effects that were manageable in the majority of cases,
although four non-progressing patients interrupted the treatment before the planned six cycles due
to intense asthenia and PS deterioration, and one toxic death was seen. The effect of EDP-M in
controlling hypercortisolism was not reported, since drugs able to induce a rapid decrease in cortisol
levels, such as metyrapone and abiraterone [16–18], were associated to the scheme in 11 patients with
Cushing syndrome.
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The present series confirms that the EDP-M scheme has a limited efficacy but still remains the most
effective therapy we actually have in the management of advanced ACC. On the basis of this single
center experience, we can provide some recommendations on how to best use the EDP-M regimen in
routine clinical practice.
In our series, five patients, who experienced an increase in the size of metastatic lesions already
present at baseline did not interrupt the treatment plan. None of them showed disease progression
at a subsequent CT scan; on the contrary, three obtained a partial disease remission and a complete
pathological response was observed in one of them at subsequent histological evaluation after surgery.
It is possible that this favorable outcome would not have been achieved if patients had suspended the
treatment plan and had received a second-line therapy. In the clinical routine practice, an antineoplastic
therapy is usually interrupted in the case of tumor progression according to the RECIST criteria.
Our data suggest that this could be not the case in ACC patients receiving EDP-M, because disease
control is subordinate not only to the cytotoxic effect of chemotherapy, but also to the achievement of
mitotane therapeutic range, which usually occurs after 2–3 months from the beginning of the therapy.
Therefore, early progression of ACC to EDP-M does not always mean treatment inefficacy; as a matter
of fact, three patients with early disease progression obtained a partial response subsequently, in
conjunction with the achievement of mitotane concentrations within therapeutic levels. Our data are
consistent with a recently published case report [19].
The present paper also underlines the importance of a multidisciplinary approach in the
management of ACC. All patients in our series without disease progression after 4–6 months were
discussed by our multidisciplinary team and were pinpointed for surgery if a complete surgical
removal of the disease was deemed feasible or the residual disease was estimated to be ≤10%.
As expected, patients who underwent surgery had a better outcome in terms of PFS and OS than
those who did not. Of course, this does not mean that surgery in this setting is per se efficacious,
since patients earmarked for surgery were selected among those already destined to have a good
prognosis. However, post-chemotherapy surgery provided the advantage of reassessing the tumor
after therapy. In our study, four patients (7%) attained a pathological complete response and none
of them had recurred at the last follow-up. A pCR after EDP-M has already been described by our
group in a single patient [20], who obtained a long-term survival. The finding of a 7% pCR rate in
this series suggests that EDP-M could be very efficacious in a minority of ACC patients. pCR after
neoadjuvant chemotherapy in breast cancer patients is associated to a better outcome and may be
a potential surrogate of treatment efficacy [21]. Along these lines, the detection of pCR could identify
a small subgroup of ACC patients who are destined to obtain a long-term benefit from the therapy.
Another advantage of post-chemotherapy surgery is the reassessment of the proliferation activity.
Ki67 expression is a major prognostic parameter in ACC [22]. In this series, we evaluated, for the
first time, its prognostic role in residual tumors after EDP-M and observed that this marker, categorized
by the median value, identified two patient groups with divergent PFS and OS. In early breast
cancer patients, Ki67 immunostaining after neoadjuvant chemotherapy was found to have a stronger
prognostic significance than its expression at baseline conditions [23]. In addition, Ki67 is a good
intermediate marker to predict the efficacy of neoadjuvant hormone therapy [24,25]. Therefore, Ki67 at
residual histology after EDP in ACC patients could have the same significance as in breast cancer and
this issue deserves to be further explored. Noteworthily, in the patient subset who had surgery after
EDP-M, who were carefully selected, we also evaluated the prognostic role of Ki67 assessed at baseline
and an opposite result was observed, i.e., patients with higher Ki67 had a better prognosis. It should be
noted that these patients were selected among those attaining a disease response after EDP-M and it is
well known that chemotherapy efficacy is directly correlated with tumor proliferative activity. This is
a possible explanation for the discrepant prognostic role of Ki67 observed before and after EDP-M.
It should be noted, in any case, that baseline Ki67 in the majority of these patients was assessed in
specimens obtained by a Tru-Cut biopsy and this has limited the accuracy of the assessment.
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4. Patients and Methods
This is a monocentric, retrospective study. Consecutive ACC patients treated with the EDP-M
scheme at ASST Spedali Civili of Brescia were included.
All patients met the conventional eligibility criteria adopted for chemotherapy in adult ACC
patients: age >18 years; Eastern Cooperative Oncology Group (ECOG) PS0–2; pathological diagnosis
of ACC; locally advanced or metastatic disease not suitable for surgery; at least one unidimensional
(RECIST criteria) measurable lesion; adequate bone marrow reserve (neutrophils ≥1500/mm3 and
platelets ≥100,000/mm3, hemoglobin ≥9.0 g/dl); total bilirubin ≤1.5 times the upper limit of normal;
serum creatinine ≤1.5 the upper limit of normal; effective contraception in premenopausal female and
male patients; written informed consent. The patient could have had a history of prior malignancy
radically resected with no evidence of disease for at least 3 years.
Exclusion criteria were the contraindications to chemotherapy, such as active clinically serious
infections (greater than grade 2 National Cancer Institute Common Toxicity Criteria (NCI-CTC) version
3.0); decompensated heart failure (ejection fraction ≥45%); myocardial infarction or revascularization
procedure during the previous 6 months; unstable angina pectoris; uncontrolled cardiac arrhythmia;
hypertension not controlled by medications; pregnancy or breast-feeding conditions.
EDP-M was administered with the following scheme: etoposide 100 mg/m2 (day 2–3–4),
doxorubicin 20 mg/m2 (day 1), cisplatin 40 mg/m2 (day 3–4) [9]. Intravenous chemotherapy
administration was performed every 4 weeks, for a maximum of 6-8 cycles. Treatment was delayed in the
case of a neutrophil count <1500/mm3, platelet count <100,000/mm3, or grade >2 extra- hematological
toxicity on treatment recycle. Moreover, a dose reduction was planned in the case of a neutrophil
count <500/mm3 and/or platelet count <30,000/mm3 experienced at recycle. All patients received
a prophylactic treatment with long-acting granulocyte colony-stimulating factor (G-CSF) after every
chemotherapy cycle (administered 48 h after the end of the cycle, by subcutaneous injection).
From 2016 onwards, drugs able to induce a rapid reduction of serum cortisol levels such as
metyrapone [16] or abiraterone [17,18] were associated to the EDP-M in the first month of therapy.
Oral mitotane was administered concomitantly with chemotherapy at a starting dose of 1500 mg
daily, with further progressive dose increments up to the maximum tolerated dose. Serum mitotane
was monitored every 4 weeks and when the patients attained the therapeutic range, the mitotane dose
was tapered to maintain serum concentration within 14 and 20 mg/L.
CT scan and/or MRI were performed at baseline and every two cycles. Radiological response
was assessed according to RECIST criteria [26]. Early PD after the first two cycles was not considered
a strict criteria of treatment interruption. At each imaging reassessment, the patient was evaluated by
a multidisciplinary team composed of medical oncologists, internal medicine physicians, surgeons and
radiologists to discuss the further steps. A surgical approach with radical intent was decided if
the patients attained a partial response or a stable disease after EDP-M and their metastatic disease
appeared suitable for surgery. Cytoreductive surgery was also considered in patients with residual
disease estimated to be ≤10%. For patients who underwent surgery, the Ki67% value at residual disease
was assessed.
All included patients had given their written informed consent to the diagnostic and
treatment procedures.
The following demographic, clinical, pathological and treatment data were collected: sex, age,
medical history, physical examination, performance status, routine laboratory tests, endocrine work-up,
chest and abdominal CT scan.
The stage of disease was assessed using the modified ENSAT (mENSAT) classification: stage III
(invasion of tissues/organs or the vena renalis/cava) and stage IVa, IVb, IVc (2, 3 or>3 metastatic organs,
including N, respectively) [14].
We categorized the patients according to the GRAS score, considering grading, R status, age and
symptoms, defined as tumor- or hormone-related symptoms at diagnosis [14]. GRAS score was defined
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as GRAS 1 (favorable): ≤1 risk factor in GRAS parameters; GRAS 2 (unfavorable): 2 risk factors in
GRAS parameters; GRAS 3 (pejorative): ≥3 risk factors in GRAS parameters.
PFS was defined as the time elapsed from the beginning of the EDP-M treatment until
disease progression or death. Non-progressing patients still alive were censored at the last
follow-up examination.
OS was defined as the time interval between the date of EDP-M treatment start and the date of
death from any cause or the last known date when the patient was alive.
The retrospective study was approved by the Ethical Review Board of ASST-Spedali Civili in
Brescia (protocol no 3229; version 1.1, 1st December 2019).
Descriptive statistics were used to analyze the patients’ clinical characteristics. Survival curves
were calculated by the Kaplan–Meier method and differences were compared by the log rank test.
Statistical significance was set at p < 0.05. SPSS v23.0 software was used for the statistical analyses
(SPSS Inc., Chicago, IL, USA).
5. Conclusions
EDP-M is confirmed as having a limited efficacy in the management of advanced/metastatic
ACC patients, although a small proportion of patients can obtain a long-term clinical benefit.
Early progression to EDP-M does not always mean treatment inefficacy and treatment discontinuation
would not be advisable in progressing patients without the appearance of new lesions, in whom
serum mitotane levels have not reached therapeutic concentrations. Surgery of residual disease in
responding patients allows for the detection of pCR in few of them and this condition is predictive of
long-term clinical outcomes. The reassessment of proliferation activity by Ki67 immunostaining in
post-chemotherapy surgical specimens could be an additional prognostic parameter that deserves to
be studied further.
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